Compare Synopsys, Inc. (SNPS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Twist Bioscience Corp — how do they compare? Synopsys, Inc. trades at $387 (market cap $72.47B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Synopsys, Inc. is far larger — about 13.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | TWST | |
|---|---|---|
Market Cap | $72.47B | $5.45B |
Sector | Technology | Health |
52-Week High | $645.59 | $102.88 |
52-Week Low | $378.46 | $24.16 |
Enterprise Value | $80.82B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $388.84, up 1.19% on the day, with a bearish technical signal despite recent earnings beats. The stock faces headwinds from semiconductor sector volatility but maintains strong analyst support with an 82.76% buy rating. Recent news highlights the company's strategic pivot toward AI design tools and margin expansion following its Ansys integration, positioning it as a key enabler in the chip design ecosystem despite near-term price pressure.
Outlook remains positive long-term due to SNPS's dominant EDA market position and AI-driven growth opportunities, though investors face risks from cyclical semiconductor demand and integration execution. The consensus price target of $559.50 implies significant upside if the company delivers on its AI strategy and margin improvements.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
